Statement Of Cash Flows [Abstract]
| Concept |
2022-01-01 to 2022-12-31 |
2021-01-01 to 2021-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) operating activities [abstract] | ||
| Adjustments for finance income (cost) |
151,000,000
EUR
|
149,000,000
EUR
|
| Increase (decrease) in working capital |
461,000,000
EUR
|
25,000,000
EUR
|
| Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss |
635,000,000
EUR
|
697,000,000
EUR
|
| Adjustments for gains (losses) on change in fair value less costs to sell, biological assets |
195,000,000
EUR
|
328,000,000
EUR
|
| Adjustments for undistributed profits of investments accounted for using equity method |
221,000,000
EUR
|
143,000,000
EUR
|
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of interests in investments accounted for using equity method |
7,000,000
EUR
|
6,000,000
EUR
|
| Proceeds from sales of investments accounted for using equity method |
10,000,000
EUR
|
47,000,000
EUR
|
| Purchase of biological assets |
101,000,000
EUR
|
79,000,000
EUR
|
| Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
603,000,000
EUR
|
565,000,000
EUR
|
| Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
17,000,000
EUR
|
105,000,000
EUR
|
| Cash flows from (used in) financing activities [abstract] | ||
| Proceeds from non-current borrowings |
366,000,000
EUR
|
19,000,000
EUR
|